The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents
Open accessAbstract
Key Points: MMB ameliorates anemia in a rodent anemia of chronic disease model by inhibiting activin receptor-like kinase-2 activity. Hepcidin-dependent ferroportin degradation is independent of JAK2 phosphorylation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization
Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., Ward, D. M., Ganz, T., & Kaplan, J. (2004) · Science · doi:10.1126/science.1104742 · Cited by 4,803
Weiss, G., & Goodnough, L. T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041809 · Cited by 3,800
Hepcidin, a urinary antimicrobial peptide synthesized in the liver
Park, C. H., Valore, E. V., Waring, A. J., & Ganz, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008922200 · Cited by 2,168
Two to tango: Regulation of Mammalian iron metabolism
Hentze, M. W., Muckenthaler, M. U., Galy, B., & Camaschella, C. (2010) · Cell · doi:10.1016/j.cell.2010.06.028 · Cited by 2,120
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110557 · Cited by 2,103
Pigeon, C., Ilyin, G., Courselaud, B., Leroyer, P., Turlin, B., Brissot, P., & Loréal, O. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008923200 · Cited by 1,697
LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity
Krause, A., Neitz, S., Mägert, H.-J., Schulz, A., Forssmann, W.-G., Schulz-Knappe, P., & Adermann, K. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01920-7 · Cited by 1,324
Ganz, T. (2013) · Physiological Reviews · doi:10.1152/physrev.00008.2013 · Cited by 1,122
BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism
Andriopoulos Jr, B., Corradini, E., Xia, Y., Faasse, S. A., Chen, S., Grgurevic, L., Knutson, M. D., Pietrangelo, A., Vukicevic, S., Lin, H. Y., et al. (2009) · Nature Genetics · doi:10.1038/ng.335 · Cited by 769
Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats
Theurl, I., Schroll, A., Sonnweber, T., Nairz, M., Theurl, M., Willenbacher, W., Eller, K., Wolf, D., Seifert, M., Sun, C. C., et al. (2011) · Blood · doi:10.1182/blood-2011-03-345066 · Cited by 189
Self-citation
Research works printed but not linked: 20
- Theurl, 2009, Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications, Blood, 113, 5277, 10.1182/blood-2008-12-195651 · DOI · Paper page
- Wang, 2005, A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression, Cell Metab, 2, 399, 10.1016/j.cmet.2005.10.010 · DOI · Paper page
- Meynard, 2009, Lack of the bone morphogenetic protein BMP6 induces massive iron overload, Nat Genet, 41, 478, 10.1038/ng.320 · DOI · Paper page
- Zhao, 2013, Iron regulation by hepcidin, J Clin Invest, 123, 2337, 10.1172/JCI67225 · DOI · Paper page
- Steinbicker, 2011, Perturbation of hepcidin expression by BMP type I receptor deletion induces iron overload in mice, Blood, 118, 4224, 10.1182/blood-2011-03-339952 · DOI · Paper page
- Steinbicker, 2011, Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation, Blood, 117, 4915, 10.1182/blood-2010-10-313064 · DOI · Paper page
- Theurl, 2011, Pathways for the regulation of hepcidin expression in anemia of chronic disease and iron deficiency anemia in vivo, Haematologica, 96, 1761, 10.3324/haematol.2011.048926 · DOI
- Tefferi, 2012, One thousand patients with primary myelofibrosis: the mayo clinic experience, Mayo Clin Proc, 87, 25, 10.1016/j.mayocp.2011.11.001 · DOI · Paper page
- Pardanani, 2013, Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis, Am J Hematol, 88, 312, 10.1002/ajh.23406 · DOI
- Pardanani, 2013, Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis, Leukemia, 27, 1322, 10.1038/leu.2013.71 · DOI · Paper page
- Verstovsek, 2010, Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis, N Engl J Med, 363, 1117, 10.1056/NEJMoa1002028 · DOI · Paper page
- Parganas, 1998, Jak2 is essential for signaling through a variety of cytokine receptors, Cell, 93, 385, 10.1016/S0092-8674(00)81167-8 · DOI · Paper page
- Neubauer, 1998, Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis, Cell, 93, 397, 10.1016/S0092-8674(00)81168-X · DOI · Paper page
- De Domenico, 2009, Hepcidin-induced internalization of ferroportin requires binding and cooperative interaction with Jak2 [published correction appears in Proc Natl Acad Sci USA. 2012;109(19):7583-7586], Proc Natl Acad Sci USA, 106, 3800, 10.1073/pnas.0900453106 · DOI
- Krempler, 2004, Generation of a conditional knockout allele for the Janus kinase 2 (Jak2) gene in mice, Genesis, 40, 52, 10.1002/gene.20063 · DOI
- Lee, 2005, Regulation of hepcidin transcription by interleukin-1 and interleukin-6, Proc Natl Acad Sci USA, 102, 1906, 10.1073/pnas.0409808102 · DOI · Paper page
- Wrana, 2013, Signaling by the TGFβ superfamily, Cold Spring Harb Perspect Biol, 5, a011197, 10.1101/cshperspect.a011197 · DOI
- Besson-Fournier, 2017, Hepcidin upregulation by inflammation is independent of Smad1/5/8 signaling by activin B, Blood, 129, 533, 10.1182/blood-2016-10-748541 · DOI
- Strati, 2014, Clinical significance of microcytosis in patients with primary myelofibrosis, Leuk Res, 38, 1212, 10.1016/j.leukres.2014.08.007 · doi:10.1016/j.leukres.2014.08.007
- Vainchenker, 2013, Myelofibrosis, JAK2 inhibitors and erythropoiesis, Leukemia, 27, 1219, 10.1038/leu.2013.72 · DOI
Cited by
Iron metabolism and iron disorders revisited in the hepcidin era
Camaschella, C., Nai, A., & Silvestri, L. (2020) · Haematologica · doi:10.3324/haematol.2019.232124 · Cited by 734
Ganz, T. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1804281 · Cited by 589
Mesa, R. A., Kiladjian, J.-J., Catalano, J. V., Devos, T., Egyed, M., Hellmann, A., McLornan, D., Shimoda, K., Winton, E. F., Deng, W., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.4418 · Cited by 387
Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update
Roskoski, R. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107059 · Cited by 383
Harrison, C. N., Vannucchi, A. M., Platzbecker, U., Cervantes, F., Gupta, V., Lavie, D., Passamonti, F., Winton, E. F., Dong, H., Kawashima, J., et al. (2018) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30237-5 · Cited by 321
Metadata
- Authors
- Asshoff, M., Petzer, V., Warr, M. R., Haschka, D., Tymoszuk, P., Demetz, E., Seifert, M., Posch, W., Nairz, M., Maciejewski, P., Fowles, P., Burns, C. J., Smith, G., Wagner, K.-U., Weiss, G., Whitney, J. A., & Theurl, I.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2017-03-30
- Volume
- 129
- Issue
- 13
- Pages
- 1823-1830
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2586215211
- Cited by
- 233
- References
- 12
- FWCI
- 12.49
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents. https://app.cochat.ai/papers/10.1182/blood-2016-09-740092
- The paper
- Asshoff, M., Petzer, V., Warr, M. R., Haschka, D., Tymoszuk, P., Demetz, E., Seifert, M., Posch, W., Nairz, M., Maciejewski, P., Fowles, P., Burns, C. J., Smith, G., Wagner, K.-U., Weiss, G., Whitney, J. A., & Theurl, I. (2017). Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents. Blood. https://doi.org/10.1182/blood-2016-09-740092
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.